Literature DB >> 21820606

MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.

Zhao-Xia Wang1, Bin-Bin Lu, He Wang, Zhi-Xiang Cheng, Yong-Mei Yin.   

Abstract

BACKGROUND AND AIMS: Ovexpression of microRNA-21 (miR-21) is found in various human cancers. Our aim is to investigate the association of miR-21 expression with the sensitivity of breast cancer cells to doxorubicin (ADR).
METHODS: The half maximal inhibitory concentration (IC(50)) value of ADR in resistant MCF-7/ADR or parental MCF-7 cells was determined by MTT assay. TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-21 and tumor suppressor gene (PTEN) protein. MCF-7 or MCF-7/ADR cell line was transfected with miR-21mimic or inhibitor. The IC(50) value of ADR was determined. Flow cytometry and TUNEL assays were performed to analyze apoptosis. The activity of caspase-3 was analyzed.
RESULTS: The IC(50) of ADR in MCF-7 and MCF-7/ADR cells was 0.21 ± 0.05 and 16.5 ± 0.08 μmol/L, respectively. We showed that upregulation of miR-21 in MCF-7/ADR cells was concurrent with downregulation of PTEN protein. MiR-21 mimic or inhibitor could obviously affect the sensitivity of breast cancer cells to ADR. Moreover, miR-21 inhibitor could enhance caspase-3-dependent apoptosis in MCF-7/ADR cells. Overexpression of PTEN could mimic the same effects of miR-21 inhibitor in MCF-7/ADR cells and PTEN-siRNA could increase the resistance of MCF-7 cells to ADR. MiR-21 inhibitor could increase PTEN protein expression and the luciferase activity of a PTEN 3' untranslated region-based reporter construct in MCF-7/ADR cells. PTEN-siRNA could partially reverse the increased chemosensitivity of MCF-7/ADR cells induced by miR-21 inhibitor.
CONCLUSIONS: Dysregulation of miR-21 plays critical roles in the ADR resistance of breast cancer, at least in part via targeting PTEN.
Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820606     DOI: 10.1016/j.arcmed.2011.06.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  53 in total

1.  MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways.

Authors:  Bo Gong; Wan-Wei Liu; Wen-Jing Nie; Dong-Feng Li; Zi-Jun Xie; Chao Liu; Yan-Hui Liu; Ping Mei; Zi-Jun Li
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN.

Authors:  Xiaomin Yu; Yulong Chen; Ruiyun Tian; Jianxia Li; Hongyan Li; Teng Lv; Qin Yao
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

Review 3.  Role of microRNAs in breast cancer.

Authors:  Ramesh Singh; Yin-Yuan Mo
Journal:  Cancer Biol Ther       Date:  2013-01-04       Impact factor: 4.742

4.  Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells.

Authors:  Petra Faltejskova; Andrej Besse; Sabina Sevcikova; Lenka Kubiczkova; Marek Svoboda; Jan Smarda; Igor Kiss; Rostislav Vyzula; Ondrej Slaby
Journal:  Int J Colorectal Dis       Date:  2012-04-03       Impact factor: 2.571

5.  Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis.

Authors:  Laura Giunti; Martina da Ros; Serena Vinci; Stefania Gelmini; Anna Lisa Iorio; Anna Maria Buccoliero; Stefania Cardellicchio; Francesca Castiglione; Lorenzo Genitori; Maurizio de Martino; Sabrina Giglio; Maurizio Genuardi; Iacopo Sardi
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 6.  miRNA - Therapeutic tool in breast cancer? Where are we now?

Authors:  Karolina Zaleska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-26

7.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

Review 8.  MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications.

Authors:  Wei Tian; Junqing Chen; Haifei He; Yongchuan Deng
Journal:  Clin Transl Oncol       Date:  2012-08-23       Impact factor: 3.405

9.  Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Josiah Cox; Steven Weinman
Journal:  Hepat Oncol       Date:  2016-01-01

10.  MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway.

Authors:  Chen Lv; Yuehan Hao; Guanjun Tu
Journal:  Tumour Biol       Date:  2016-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.